Abstract 3808: The Effect of High Loading Dose of Rosuvastatin before Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome
Background: High dose loading of statin prior to percutaneous coronary intervention (PCI) may be associated with reduced periprocedural myocardial injury after PCI and major adverse cardiac events (MACE).
Methods: Consecutive 152 patients with acute coronary syndrome (ACS) who underwent PCI were randomly assigned to either the group of no statin treatment before PCI (Group I: n=76) or the group of 40 mg rosuvastatin loading before PCI (Group II: n=76). Incidence of periprocedural myocardial injury was assessed by analysis of creatinine kinase-MB (CK-MB) and cardiac troponin T before PCI, at 6 hours and the next morning after PCI. In-hospital and 30-day MACE were compared between the two groups.
Results: There were no significant differences in clinical characteristics between the two groups. After PCI, peak value of cardiac enzymes were significantly higher in Group I than in Group II (p=0.025 in CK-MB, p=0.020 in troponin T). In-hospital and 30-day MACE were higher in Group I than in Group II (9.2% vs. 2.6%, p=0.083; 15.8% vs. 3.9%, p=0.013). Multivariate analysis revealed that no prior use of statin was the only independent prognostic indicator for MACE.
Conclusion: Single high dose of rosuvastatin prior to PCI reduces in-hospital and 30 day MACE and periprocedural myocardial injury in patients with ACS.